Table 3.
Replacement therapy details in pregnant hemophilia carriers.
| Treatment Characteristics | Frequency n = 64 | % |
|---|---|---|
| Type of Replacement Therapy | ||
| Plasma derived factor VIII | 8 | 12.5 |
| Recombinant factor VIII | 56 | 87.5 |
| Dosage (IU/kg per week) | ||
| Median (IQR) | 30 (25–40) | |
| Frequency of Administration | ||
| Once weekly | 12 | 18.8 |
| Twice weekly | 18 | 28.1 |
| Three times weekly | 10 | 15.6 |
| Other | 24 | 37.5 |
| Duration of Therapy (weeks) | ||
| Median (IQR) | 28 (24–32) | |
| Reason for Replacement Therapy Use | ||
| Bleeding episodes management | 42 | 65.6 |
| Surgery preparation | 8 | 12.5 |
| Prophylactic during pregnancy | 14 | 21.9 |
| Switch of Therapy | ||
| From recombinant to plasma derived | 2 | 3.1 |
| From plasma derived to recombinant | 6 | 9.4 |